Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

(2017) Mathias J. Rummel et al.   JOURNAL OF CLINICAL ONCOLOGY

Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management

(2012) Julie M. Vose   AMERICAN JOURNAL OF HEMATOLOGY

Guidelines for the investigation and management of mantle cell lymphoma

(2012) P. McKay et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of Older Patients with Mantle-Cell Lymphoma

(2012) H.C. Kluin-Nelemans et al.   NEW ENGLAND JOURNAL OF MEDICINE

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

(2011) T. E. Witzig et al.   ANNALS OF ONCOLOGY

Mantle cell lymphoma: The promise of new treatment options

(2010) Andre Goy et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

(2010) Zhengzi Qian et al.   LEUKEMIA RESEARCH

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

(2009) Liang Zhang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

(2009) C. S. Tam et al.   BLOOD

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

(2009) Thomas M. Habermann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

(2008) C. H. Geisler et al.   BLOOD

A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma

(2008) Andrew M. Evens et al.   BRITISH JOURNAL OF HAEMATOLOGY

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004

(2008) Yuhong Zhou et al.   CANCER

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma

(2008) Stephen M. Ansell et al.   CANCER

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

(2008) Annina Herrmann et al.   JOURNAL OF CLINICAL ONCOLOGY

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD